Pre-clinical work demonstrated that rescue of BMPR2 signaling or enhancement of endothelial BMPR2 activity with BMPR2 replacement or BMP9 supplementation halted and reversed PAH disease pathogenesis [14, 15]. Here, GDF2 is linked to pulmonary arterial hypertension.